Zuzanna Zofia Ratka

Ms. Zuzanna Zofia Ratka

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KŻKacper Żełabowski
Kacper Żełabowski
WPWiktor Manuel Petrov
Wiktor Manuel Petrov
KWKacper Wojtysiak
Kacper Wojtysiak
ZRZuzanna Zofia Ratka
Zuzanna Zofia Ratka
KBKamil Biedka
Kamil Biedka
ACAgnieszka Chłopaś-Konowałek
Agnieszka Chłopaś-Konowałek
The orexin (hypocretin) system plays a central role in regulating the sleep–wake cycle through two neuropeptides, orexin-A and orexin-B, which act on OX1R and OX2R receptors. Emerging evidence links heightened orexin signaling with the pathophysiology of chronic insomnia. This review outlines the neurobiology of the orexinergic system, compares the pharmacological profile of dual orexin receptor antagonists (DORAs) to traditional GABAergic hypnotics, and evaluates the clinical efficacy and safety of Suvorexant, Lemborexant, and Daridorexant. DORAs function by selectively dampening orexin-driven arousal, thereby facilitating sleep onset and maintenance without disrupting natural sleep architecture. Clinical trials have shown that these agents significantly reduce sleep latency and enhance sleep continuity, with a favorable side effect profile. Overall, DORAs represent a distinct and clinically advantageous option for insomnia treatment, with growing interest in their potential utility across mood, anxiety, and neurodegenerative disorders.

Verified
Journal Article
Open access
PDF file
KŻKacper Żełabowski
Kacper Żełabowski
KWKacper Wojtysiak
Kacper Wojtysiak
ZRZuzanna Zofia Ratka
Zuzanna Zofia Ratka
KBKamil Biedka
Kamil Biedka
ACAgnieszka Chłopaś-Konowałek
Agnieszka Chłopaś-Konowałek
Lamotrigine is the drug of choice for the treatment of depressive episodes in bipolar disorder (BD). Despite its generally favorable tolerability profile, lamotrigine use is associated with a risk of Cutaneous Adverse Drug Reactions (cADRs), including Stevens–Johnson Syndrome (SJS) and Lyell’s syndrome, also known as toxic epidermal necrolysis (TEN). Genetic markers HLA and, in particular, HLA-B 15:02 and HLA-A 31:01 are crucial in predicting individuals’ susceptibility to developing the symptoms. The symptoms are triggered by type IV hypersensitivity developing because of CTL and NK cell activation, leading to keratinocyte apoptosis, epidermal necrosis and skin detachment. The exact pharmacotherapy that should be widely utilized in treating affected patients has not yet been established. New therapies including JAK inhibitors or cyclosporine show potential in improving outcomes by reducing mortality and enhancing the period of recovery. Key factors in preventing cADRs may include adequate patient observation, gradual titration of the patient’s dose, and reduction of risk factors through screening for HLA polymorphisms. When the initial symptoms of cADR are identified, it is imperative to make an immediate decision to discontinue treatment, as this can significantly reduce the risk of progression to SJS/TEN and systemic complications. The purpose of this review is to identify a significant correlation between lamotrigine use in BD and the occurrence of SJS by showing the risk factors, neuropharmacological mechanisms, immune response and correctness of pharmacotherapy.

14 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KŻKacper Żełabowski
Kacper Żełabowski
WPWiktor Manuel Petrov
Wiktor Manuel Petrov
DŚDawid Ślebioda
Dawid Ślebioda
MRMalwina Rusinek
Malwina Rusinek
KBKamil Biedka
Kamil Biedka
ACAgnieszka Chłopaś-Konowałek
Agnieszka Chłopaś-Konowałek
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder generally associated with pediatric patients and in lesser extent with adults. Patients diagnosed with ADHD have a higher likelihood of developing addiction. Consequently, a disorder that frequently co-occurs with ADHD is Substance Use Disorder (SUD). The pharmaceuticals prescribed in the treatment of ADHD are predominantly stimulants, such as methylphenidate and amphetamines, which possess a high addiction potential. The objective of this study is to examine the risk of developing substance dependence during stimulant treatment in individuals with ADHD who have a natural predisposition to addiction, with particular emphasis on adult patients with a history of SUD. Our literature review was conducted using research papers from PubMed, Google Scholar, Embase, ProQuest and ScienceDirect. The main results from our review are as follows: (i) the majority of studies indicate that the administration of stimulants in the treatment of ADHD does not increase the risk of developing Substance Use Disorder; (ii) stimulants may also be used in the treatment of SUD; (iii) while pharmacotherapy is a crucial part of ADHD treatment, a holistic approach comprising pharmacological and non-pharmacological therapy is most effective; (iv) holistic management of ADHD is necessary to improve patients’ quality of life to the greatest extent possible.

Verified
Journal Article
Open access
PDF file
ZRZuzanna Zofia Ratka
Zuzanna Zofia Ratka
AGAndrzej Gamian
Andrzej Gamian
MWMarta Woźniak
Marta Woźniak
Epithelial ovarian cancer (EOC) remains one of the most lethal gynecologic malignancies, largely owing to advanced-stage presentation, high rates of relapse, and the eventual emergence of therapeutic resistance. Despite the transformative success of immune checkpoint inhibitors (ICIs) across multiple solid tumors, their clinical impact in ovarian cancer has been comparatively modest. This literature review provides a comprehensive synthesis of recent advances in ICI strategies for ovarian cancer (OC), with particular emphasis on phase II and III clinical trials evaluating programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), and T cell immunoglobulin and mucin-domain-containing-3 (TIM-3)-directed therapies. Accumulating evidence indicates that PD-1/PD-L1 monotherapy yields limited clinical activity in unselected OC populations, with low objective response rates and minimal survival benefit. Dual checkpoint blockade with PD-1 and CTLA-4 inhibitors demonstrates enhanced antitumor activity, particularly in clear cell ovarian carcinoma (CCOC), albeit at the expense of increased immune-related toxicity. Large randomized trials incorporating ICI into first-line chemotherapy or maintenance settings have largely failed to improve outcomes in biomarker-unselected cohorts. Available evidence demonstrates that combinatorial approaches integrating ICI with anti-angiogenic agents, PARP inhibitors, or neoadjuvant chemotherapy provide modest benefit in selected molecular and histologic subgroups. Early-phase investigations of TIM-3–targeting strategies further expand the immunotherapeutic landscape, although clinical efficacy remains preliminary. Current evidence underscores that OC is not uniformly responsive to immunotherapy and that rational combination strategies, biomarker-driven patient selection, and improved understanding of tumor immune microenvironment heterogeneity are essential to unlocking the full therapeutic potential of ICI in this disease.

Verified
Journal Article
Open access
PDF file
KWKacper Wojtysiak
Kacper Wojtysiak
ZRZuzanna Zofia Ratka
Zuzanna Zofia Ratka
ACAgnieszka Chłopaś-Konowałek
Agnieszka Chłopaś-Konowałek
Long-term treatment with attention-deficit/hyperactivity disorder (ADHD) medications may begin before reproductive maturity, but their effects on male reproductive health remain uncertain. We systematically evaluated controlled in vivo mammalian evidence on male reproductive effects of medications used for ADHD, including the consistency, timing, reversibility, and certainty of reported associations. PubMed/MEDLINE, Embase, and Scopus were searched from inception to 8 August 2026. Eligible studies were English-language, controlled in vivo mammalian experiments evaluating a prespecified ADHD medication and at least one male reproductive outcome. Human, in-vitro-only, uncontrolled, conference-abstract, and preprint reports were excluded. Risk of bias was independently assessed by two reviewers using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool, and certainty was evaluated using an adapted preclinical Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Results were grouped by drug and nine prespecified outcome domains and synthesized narratively. Meta-analysis was not performed because of substantial methodological and outcome heterogeneity. Twenty-two studies were included: 19 evaluated methylphenidate (MPH), two clonidine, and one lisdexamfetamine (LDX); 17 were conducted in rats, four in mice, and one in rhesus macaques. During active MPH exposure, adverse changes predominated in spermatogenesis, sperm quantity or quality, testicular or epididymal microstructure, testosterone, and apoptotic or inflammatory markers. Findings after drug-free follow-up were more often neutral, mixed, or partially reversible. Possible persistent sperm DNA fragmentation and adverse paternal embryonic outcomes were reported but were based on few studies with clustering concerns. Clonidine studies indicated altered epididymal contractility and transport, whereas the single high-dose LDX study reported adverse sperm, testicular, endocrine, DNA-fragmentation, and inflammatory findings. Risk-of-bias assessments were dominated by unclear judgments. None of the 18 drug-by-outcome-domain bodies of evidence reached high or moderate certainty; all were rated as very low certainty. Evidence was limited by small samples, heterogeneous species, developmental stages, doses, routes, exposure durations and assays, incomplete numerical reporting, serious indirectness to therapeutic use in men, and sparse replication outside MPH. ADHD medications, particularly MPH during active exposure, show a possible male reproductive toxicity signal in animal models, but the evidence does not permit quantitative risk estimation or class-wide or clinical conclusions. Better-controlled, exposure-validated animal studies and prospective human cohorts are needed.